These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 3269674)

  • 41. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
    Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Leukocyte and platelet-derived factors augment canine coronary constriction to serotonin.
    Cappelli-Bigazzi M; Lamping KG; Nuno DW; Harrison DG
    Am J Physiol; 1990 Oct; 259(4 Pt 2):H1161-70. PubMed ID: 2171364
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Suppression of prostanoid formation and regulation of peripheral circulation after surgery using thrombin inhibitor (MD805).
    Onizuka M; Ishikawa S; Ishibashi O; Suga M; Mitsui K; Mitsui T
    Surg Today; 1998; 28(6):618-25. PubMed ID: 9681611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of thromboxane A2 inhibition on osteogenic sarcoma cell-induced platelet aggregation.
    Mehta P; Lawson D; Ward MB; Lee-Ambrose L; Kimura A
    Cancer Res; 1986 Oct; 46(10):5061-3. PubMed ID: 3463411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Direct thrombin inhibitors.
    Di Nisio M; Middeldorp S; Büller HR
    N Engl J Med; 2005 Sep; 353(10):1028-40. PubMed ID: 16148288
    [No Abstract]   [Full Text] [Related]  

  • 46. Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition.
    Brito FC; Kummerle AE; Lugnier C; Fraga CA; Barreiro EJ; Miranda AL
    Eur J Pharmacol; 2010 Jul; 638(1-3):5-12. PubMed ID: 20412790
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of serotonin, histamine, and thromboxane A2 in platelet-induced contractions of coronary arteries and aortae from rabbits.
    Awano K; Yokoyama M; Fukuzaki H
    J Cardiovasc Pharmacol; 1989 May; 13(5):781-92. PubMed ID: 2472528
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion.
    Yao SK; McNatt J; Anderson HV; Eidt J; Cui KX; Golino P; Glas-Greenwalt P; Maraganore J; Buja LM; Willerson JT
    Am J Physiol; 1992 Feb; 262(2 Pt 2):H374-9. PubMed ID: 1539695
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiac-derived thromboxane A2. An initiating mediator of reperfusion injury?
    Byrne JG; Appleyard RF; Sun SC; Couper GS; Sloane JA; Laurence RG; Cohn LH
    J Thorac Cardiovasc Surg; 1993 Apr; 105(4):689-93. PubMed ID: 8469003
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coronary vascular reactivity after acute myocardial ischemia.
    Ku DD
    Science; 1982 Nov; 218(4572):576-8. PubMed ID: 7123259
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heparin-induced platelet aggregation is inhibited by antagonists of the thromboxane pathway.
    Brace LD; Issleib S; Fareed J
    Thromb Res; 1986 Nov; 44(3):417-8. PubMed ID: 3798406
    [No Abstract]   [Full Text] [Related]  

  • 52. Thrombin-induced vasoconstriction in isolated cerebral arteries and the influence of a synthetic thrombin inhibitor.
    Nakamura K; Hatano Y; Mori K
    Thromb Res; 1985 Dec; 40(5):715-20. PubMed ID: 4089836
    [No Abstract]   [Full Text] [Related]  

  • 53. In vitro and in vivo properties of synthetic inhibitors of thrombin: recent advances.
    Okamoto S; Wanaka K; Hijikata-Okunomiya A
    Adv Exp Med Biol; 1993; 340():119-30. PubMed ID: 8154329
    [No Abstract]   [Full Text] [Related]  

  • 54. [The regulatory system of platelet aggregation during hyperbaric oxygenation].
    Ekimov VV; Reznikov KM
    Gematol Transfuziol; 1989 Jun; 34(6):49-53. PubMed ID: 2680750
    [No Abstract]   [Full Text] [Related]  

  • 55. Dimethyl sulfoxide inhibits platelet aggregation in partially obstructed canine coronary vessels.
    Pace DG; Kovacs JL; Klevans LR
    Ann N Y Acad Sci; 1983; 411():352-6. PubMed ID: 6576712
    [No Abstract]   [Full Text] [Related]  

  • 56. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion.
    Okamoto S; Hijikata A; Kikumoto R; Tonomura S; Hara H; Ninomiya K; Maruyama A; Sugano M; Tamao Y
    Biochem Biophys Res Commun; 1981 Jul; 101(2):440-6. PubMed ID: 7306088
    [No Abstract]   [Full Text] [Related]  

  • 57. [On thrombin circulation in the blood].
    SUBAIROW DM
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1962; 79():62-75. PubMed ID: 13918088
    [No Abstract]   [Full Text] [Related]  

  • 58. Thrombin is an important mediator of cyclic coronary blood flow variations due to platelet aggregation in stenosed canine coronary arteries.
    Eidt JF; Allison P; Noble S; Ashton J; Golino P; McNatt J; Buja LM; Willerson JT
    Trans Assoc Am Physicians; 1988; 101():125-36. PubMed ID: 3269674
    [No Abstract]   [Full Text] [Related]  

  • 59. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.
    Eidt JF; Allison P; Noble S; Ashton J; Golino P; McNatt J; Buja LM; Willerson JT
    J Clin Invest; 1989 Jul; 84(1):18-27. PubMed ID: 2661588
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries.
    Yao SK; Ober JC; McNatt J; Benedict CR; Rosolowsky M; Anderson HV; Cui K; Maffrand JP; Campbell WB; Buja LM
    Circ Res; 1992 Jan; 70(1):39-48. PubMed ID: 1727687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.